Molnupiravir, also known by its brand name Lagevrio, represents a significant advancement in the battle against the virus. This oral antiviral compound works by introducing errors into the SARS-CoV-2's genetic code, effectively stopping its replication and progression within the patient. While initial data showed a considerable reduction in severe